New Path for a Gene Therapy Trial at NIH for a Rare Metabolic Disease
November 20, 2024
November 20, 2024
BETHESDA, Maryland, Nov. 20 (TNSres) -- The U.S. Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences issued the following news:
When Selecta Biosciences decided not to pursue a clinical trial on a promising gene therapy for a rare metabolic disease in 2023, it could have been the end of the research, despite years of work. Instead, NCATS and NIH's National Human Genome Research Institute (NHGRI) signed an agreeme . . .
When Selecta Biosciences decided not to pursue a clinical trial on a promising gene therapy for a rare metabolic disease in 2023, it could have been the end of the research, despite years of work. Instead, NCATS and NIH's National Human Genome Research Institute (NHGRI) signed an agreeme . . .